TMEM106B (Q9NUM4) was among the top 20 most significantly altered proteins when comparing AD vs. epilepsy (Table 3) with the highest fold change at an 18.9-fold increase (p = 3.22 x 10−6) and was a top protein candidate for validation with cell and regional localization. Here, TMEM106B is linked to Alzheimer disease.